Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. (2014).
Author(s): Attila Oláh, Balázs I. Tóth, István Borbíró, Koji Sugawara, Attila G. Szöllõsi, Gabriella Czifra, Balázs Pál, Lídia Ambrus, Jennifer Kloepper, Emanuela Camera, Matteo Ludovici, Mauro Picardo, Thomas Voets, Christos C. Zouboulis, Ralf Paus, and Tamás Bíró. A study that demonstrates the potential of CBD as a promising therapeutic agent for the treatment of acne vulgaris, due to its anti-inflammatory, lipostatic and antiproliferative effects. View study
Cannabidiol, a Nonpsychotropic Component of Cannabis, Inhibits Cue-Induced Heroin Seeking and Normalizes Discrete Mesolimbic Neuronal Disturbances. (2009)
Author(s): Yanhua Ren,1 John Whittard,1 Alejandro Higuera-Matas,2 Claudia V. Morris,1 and Yasmin L. Hurd1. Using an animal model, this study examines the effects of CBD on the self-administration of heroin and concludes that it can be used effectively in patients with heroin addiction. View study
Cannabis as a substitute for alcohol and other drugs. (2009).
Author(s): Amanda Reiman. This study was conducted based on data collected in an anonymous survey to examine the use of alcohol and drugs, and the occurrence of substitution among medicinal cannabis patients. It was found that the reasons for the substitution were: fewer adverse side effects (65%), better management of symptoms (57%) and less potential for abstinence (34%) with cannabis. As a result of this study it was found that medicinal cannabis patients have been participating in the substitution using cannabis as an alternative to alcohol, prescriptions and illicit drugs. View study
Interactions between delta9-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys. (2012).
Author(s): Jun-Xu Li* , Wouter Koek, and Charles P. France. THC does not significantly improve the positive reinforcing effects of heroin, further supporting the view that the combination of cannabinoids and opioid receptor agonists does not increase, and may reduce the abuse of individual drugs. View study
Involvement of the endocannabinoid system in drug addiction. (2006).
Author(s): Rafael Maldonado, Olga Valverde and Fernando Berrendero. Due to their properties, CB1 cannabinoid antagonists could contribute to the treatment of drug addiction, allowing the development of pharmacological compounds that can be used safely. View study
Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010. (2014).
Author(s): Marcus A. Bachhuber, MD; Brendan Saloner, PhD; Chinazo O. Cunningham, MD, MS; Colleen L. Barry, PhD, MPP. Based on the results of this study, it was determined that the medical laws on cannabis are associated with significantly lower death rates from opioid overdoses at the state level. Deeper studies are required to determine how medical cannabis laws can interact with policies aimed at preventing overdoses of opioid analgesics. View study
A Molecular Link Between the Active Component of Marijuana and Alzheimer’s Disease Pathology. (2008).
Author(s): Lisa M. Eubanks†, Claude J. Rogers†, Albert E. Beuscher IV‡, George F. Koob§, Arthur J. Olson‡, Tobin J. Dickerson†, and Kim D. Janda†. THC competitively inhibits the enzyme acetylcholinesterase (AChE) and prevents the aggregation of amyloid β peptide induced by AChE (Aβ), the key pathological marker of Alzheimer’s disease. View study
Activity of muscarinic, galanin and cannabinoid receptors in the prodromal and advanced stages in the triple transgenic mice model of Alzheimer’s disease. (2016).
Author(s): IVÁN MANUEL, LAURA LOMBARDERO, FRANK M. LAFERLA, LYDIA GIMÉNEZ-LLORT AND RAFAEL RODRÍGUEZ PUERTAS. The positive regulation of the galaninnergic and endocannabinoid systems supports the hypothesis of their neuroprotective functions, which are established before clear clinical cognitive symptoms of Alzheimer’s disease appear. View study
Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic. (2014).
Author(s): Ester Aso, and Isidre Ferrer. The cannabinoid compounds have polyvalent properties for the treatment of Alzheimer’s disease, which together promote progress towards a clinical trial. View study
Cannabidiol and other cannabinoids reduce microglial activation in vitro and in vivo: relevance to Alzheimer’s disease. (2011).
Author(s): MartínMoreno AM , Reigada D, Ramírez BG, Mechoulam R, Innamorato N, Cuadrado A, de Ceballos ML. Based on the results of this study it was found that cannabidiol (CBD) has the ability to modulate the function of the microglial cell in vitro, inducing beneficial effects in an in vivo model of Alzheimer’s disease, thus indicating that CBD has the potential to represent a new therapeutic approach to treat this disease. View study
Delta-9-tetrahydrocannabinol for nighttime agitation in severe dementia. (2006).
Author(s): Sebastian Walther . Richard Mahlberg . Uta Eichmann . Dieter Kunz. Dronabinol reduces nocturnal motor activity and agitation in patients with severe dementia. Thus, it represents a great potential for the safe treatment of alterations in dementia. View study
The role of endocannabinoid signaling in the molecular mechanisms of neurodegeneration in Alzheimer’s disease. (2014).
Author(s): Gaurav Bedsea,b, Adele Romanob, Angelo M. Lavecchiab, Tommaso Cassanoc,∗ and Silvana Gaetanib. In this study, we summarize the role of endocannabinoid signaling in Alzeimer disease and the probable mechanisms through which modulators of the endocannabinoid system provide their effects, thus highlighting how this objective could provide more advantages than other therapeutic objectives. View study
Natural Phytochemicals in the Treatment and Prevention of Dementia: An Overview. (2016).
Author(s): Rosaliana Libro, Sabrina Giacoppo, Thangavelu Soundara Rajan, Placido Bramanti and Emanuela Mazzon *. Properties and neuroprotective effects of the phytochemicals belonging to polyphenols, cannabinoids, alkaloids and isothiocyanates for the treatment and prevention of common types of dementia. View study
Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer’s disease. (2016).
Author(s): Attila Köfalvi1,2, Cristina Lemos1$, Ana M. Martín-Moreno3,4,# , Bárbara S. Pinheiro1$ , Luis García-García5 , Miguel A. Pozo5,6, Ângela Valério-Fernandes1 , Rui O. Beleza1 , Paula Agostinho1,7, Ricardo J. Rodrigues1,2, Susana J. Pasquaré3,7, Rodrigo A. Cunha1,8 , María L. de Ceballos3,4. This study was conducted on CB2R cannabinoid receptors (CB2R) in order to analyze their potential as therapeutic targets. It was found that CB2R has a general role of glucoregulation in the brain, which increases the therapeutic interest in CB2R agonists as nootropic agents.View study
Synthetic cannabinoids in dementia with agitation: case studies and literature review. (2013).
Author(s): Shabbir Amanullah, Kristin MacDougall, Nichole Sweeney, Joan Coffin, Julie Cole. A synthetic cannabinoid known as Nabilone improved psychomotor agitation, aggression and communication in patients with dementia, thus demonstrating the potential of cannabinoids in the treatment of these disorders. View study
The influence of cannabinoids on generic traits of neurodegeneration. (2013).
Author(s): S G Fagan and V A Campbell. Modulation of the cannabinoid system has shown beneficial effects and constitutes a possibility for the treatment of neurodegenerative disorders such as Parkinson’s disease. View study
Cannabis and Amyotrophic Lateral Sclerosis: Hypothetical and Practical Applications, and a Call for Clinical Trials. (2010).
Author(s): Gregory T. Carter, MD, MS1 , Mary E. Abood, PhD2 , Sunil K. Aggarwal, PhD3 , and Michael D. Weiss, MD1,4,5. It has been demonstrated Cannabis could significantly delay the progression of amyotrophic lateral sclerosis, increasing life expectancy and alleviating the burden of the disease. View study
Cannabidiol Post-Treatment Alleviates Rat Epileptic-Related Behaviors and Activates Hippocampal Cell Autophagy Pathway Along with Antioxidant Defense in Chronic Phase of Pilocarpine-Induced Seizure. (2016).
Author(s): Mahshid Hosseinzadeh1 & Sara Nikseresht1 & Fariba Khodagholi 1,2 & Nima Naderi 1,3 & Nader Maghsoudi. According to the results obtained from the study, a significant increase in the level of autophagy and the activation of the antioxidant route was observed after the administration of CBD at the beginning of the chronic phase of the pilocarpine-induced seizure. This suggests that the induction of autophagy and the activation of antioxidant defense could, in part, be involved in protection against seizures induced by pilocarpine. View study
Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy. (2014).
Author(s): Lili Yang a,n,1 , Raphael Rozenfeld b,1 , Defeng Wu b , Lakshmi A. Devi b , Zhenfeng Zhang c,n , Arthur Cederbaum. Cannabidiol prevents acute hepatic steatosis induced by alcohol in mice. The effective prevention of hepatic steatosis avoids the progressive damage caused by alcohol in the liver. View study
Evaluation of Serum Cytokines Levels and the Role of Cannabidiol Treatment in Animal Model of Asthma. (2015).
Author(s): Francieli Vuolo, Fabricia Petronilho, Beatriz Sonai, Cristiane Ritter, Jaime E. C. Hallak, Antonio Waldo Zuardi, José A. Crippa, and Felipe Dal-Pizzol. There is a great possibility that CBD can be used as a pharmacological treatment for asthma, because it can modulate the inflammatory responses of the disease. View study
Cannabinoid Receptor Type 2, but not Type 1, is Up-Regulated in Peripheral Blood Mononuclear Cells of Children Affected by Autistic Disorders. (2013).
Author(s): Dario Siniscalco, Anna Sapone, Catia Giordano, Alessandra Cirillo, Laura de Magistris, Francesco Rossi, Alessio Fasano, James Jeffrey Bradstreet, Sabatino Maione, Nicola Antonucci Springer. At present there is no absolutely effective treatment for autism, in fact the curative therapy is very difficult. These studies reflect the cannabinoid receptor CB2 as a possibility for the therapy and pharmacological management of autism. View study
Consequences of Cannabinoid and Monoaminergic System Disruption in a Mouse Model of Autism Spectrum Disorders. (2011).
Author(s): E.S. Onaivi, R. Benno, T. Halpern, M. Mehanovic, N. Schanz, C. Sanders, X. Yan, H. Ishiguro, Q-R Liu, A.L. Berzal, M.P. Viveros and S.F. Ali William Paterson. These experiments demonstrated the therapeutic potential of cannabinoids to help treat autism. View study